期刊文献+

流式细胞技术在多发性骨髓瘤诊断中的应用研究 被引量:10

Application of flow cytometry in the diagnosis of multiple myeloma
原文传递
导出
摘要 目的:探讨CD38/138/45/SSC及CD38/56/19/45/SSC四色组合流式细胞术在多发性骨髓瘤(MM)患者诊断中的临床应用。方法:采用多参数流式细胞技术,通过CD38/CD45双抗体设门,以CD38/138/45/SSC及CD38/56/19/45/SSC四色组合检测33例确诊MM患者骨髓中的浆细胞,并进行浆细胞胞浆κ/λ的检测。结果:33例MM患者中均可检测到CD38^(++)/CD138^+/CD45^(+/-)细胞群,在该细胞群中并未找到56^-/19^+的正常浆细胞,免疫表型为45^-/56^+/19^-标本26例,占79%,45^-/56^-/19^-标本5例,占15%,45^+/56^+/19^-标本2例,占6%。对上述CD38^(++)/138^+标本进行胞浆κ/λ检测,均为单克隆瘤细胞。结论:CD38/138/45/SSC及CD38/56/19/45/SSC四色流式细胞检测能精确发现恶性变的浆细胞,在MM诊断中有重要的临床意义和诊断价值。 Objective:To explore the diagnosis value of CD38/138/45/SSC and CD38/56/19/45/SSC four colour flow cytometry panel in multiple myeloma(MM).Method:We used the CD38/CD45 double antibody setting gate with CD38/138/45/SSC and CD38/56/19/45/SSC four colour panel to analyze bone marrow cytoplasm of 33 cases with MM,and detected cytoplasmκ/λin all cases.Result:All of 33 cases could be found out the CD38^++/CD138^+/CD45^+/- cells.The normal plasma cells of CD56^-/CD19^+cannot be found in the group.There were 26cases(79%)of 45^-/56^+/19^-,5cases(15%)of 45^-/56^-/19^-and 2cases(6%)of 45^+/56^+/19^-.All the cases with cytoplasmκ/λdetection were confirmed monoclonal tumor cells.Conclusion:The use of CD38/138/45/SSC and CD38/56/19/45/SSC four colour flow cytometry panel can accurately distinguish myeloma cells.It's very helpful for the diagnosis of MM.
作者 刘志伟 郭桂凤 韩泽平 郝俊文 黎毓光 LIU Zhiwei GUO Guifeng HAN Zeping HAO Yunwen LI Yuguang(Guangzhou Panyu Central Hospital, Guangzhou, 511400, China)
出处 《临床血液学杂志》 CAS 2017年第5期714-716,共3页 Journal of Clinical Hematology
基金 广州市番禺区科技工业商务和信息化局项目(No:2015-Z03-10) 广州市番禺区中心医院青年科研基金项目(No:2015-Q-02)
关键词 流式细胞技术 多发性骨髓瘤 诊断 flow cytometry multiple myeloma diagnosis
  • 相关文献

参考文献5

二级参考文献80

  • 1朱明清,耿美菊,陈黎,王爱青,吴德沛,阮长耿.多发性骨髓瘤的免疫表型特征[J].白血病.淋巴瘤,2006,15(5):347-348. 被引量:11
  • 2Mateos MV, Hemandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma[J]. N EnglJ Med, 2013, 369(5):438-447.
  • 3Rajkumar SV, Larson D, Kyle RA.Diagnosis of smoldering multi- ple myeloma[J]. N EnglJ Med, 2011, 365(5):474-475.
  • 4Korthals M, Sehnke N, Kronenwett R, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma[J]. Biol Blood Marrow Transplant, 2013, 19(7): 1109-1115.
  • 5Iwama K, Chihara D, Tsuda K, et al. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favor- able outcome in patients with multiple myeloma[K]. EurJ Haematol, 2013, 90(2):134-141.
  • 6Bradwell A, Harding S, Fourrier N, et al. Prognostic utility of intact immunoglobulin Ig'kappa/Ig'lambda ratios in multiple myeloma pa- tients[J]. Leukemia,2013, 27(1):202-207.
  • 7Corso A, Galli M, Mangiacavalli S, et al. Response-adjusted ISS (RalSS) is a simple and reliable prognostic scoring system for pre- dicting progression-free survival in transplanted patients with mul- tiple myeloma[J]. AmJ Hematol, 2012, 87(2):150-154.
  • 8Liu D, Lin P, Hu Y, et al. Immunophenotypic heterogeneity of nor- real plasma cells: comparison with minimal residual plasma cell my- eloma[J].J Clin Pathol,2012, 65(9):823-829.
  • 9Avet-Loiseau H, Durie BG, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collabora- tive project[J]. Leukemia, 2013, 27(3):711-717.
  • 10Waheed S, ShaughnessyJD, van Rhee F, et al. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols[J]. Cancer, 2011, 117(5):1001-1009.

共引文献70

同被引文献74

引证文献10

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部